Canaccord Genuity Maintains Buy on Harpoon Therapeutics, Lowers Price Target to $22

Canaccord Genuity maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and lowers the price target from $24 to $22.

Benzinga · 11/11/2019 13:26

Canaccord Genuity maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and lowers the price target from $24 to $22.